Shionogi, Inc

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1919-01-01

Employees: -

Market Cap: $13.1B

Website: https://www.shionogi.com/jp/ja/

Clinical Trials

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: S-217622

First Posted Date: 2022-06-08

Last Posted Date: 2023-05-26

Lead Sponsor: Shionogi

Target Recruit Count: 25

Registration Number: NCT05409911

Locations: 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸
Nucleus Network, Saint Paul, Minnesota, United States

and more 1 locations

A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Midazolam
Drug: Cefiderocol

First Posted Date: 2022-05-27

Last Posted Date: 2023-12-14

Lead Sponsor: Shionogi

Target Recruit Count: 14

Registration Number: NCT05395104

Locations: 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: S-217622

First Posted Date: 2022-05-05

Last Posted Date: 2023-04-24

Lead Sponsor: Shionogi

Target Recruit Count: 32

Registration Number: NCT05363215

Locations: 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Inc., Orlando, Florida, United States
🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States

and more 1 locations

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

Phase 3

Completed

Conditions: SARS-CoV-2 Infection

Interventions: Drug: S-217622
Drug: Placebo

First Posted Date: 2022-03-31

Last Posted Date: 2024-07-24

Lead Sponsor: Shionogi

Target Recruit Count: 2093

Registration Number: NCT05305547

Locations: 🇵🇰
The Aga Khan University, Karachi, Sindh, Pakistan
🇿🇦
Worthwhile Clinical Trials, Johannesburg, Gauteng, South Africa
🇿🇦
CHRU, Themba Lethu Clinic, Johannesburg, Gauteng, South Africa

and more 184 locations

A Study to Assess S-309309 in Healthy and Obese Participants

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: S-309309
Drug: Placebo
Drug: Midazolam

First Posted Date: 2022-02-21

Last Posted Date: 2023-01-11

Lead Sponsor: Shionogi

Target Recruit Count: 74

Registration Number: NCT05247970

Locations: 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States

A Study of S-268019 for the Prevention of COVID-19

Phase 3

Completed

Conditions: SARS-CoV-2

Interventions: Drug: S-268019-b
Drug: Placebo

First Posted Date: 2022-01-28

Last Posted Date: 2023-07-25

Lead Sponsor: Shionogi

Target Recruit Count: 9902

Registration Number: NCT05212948

Locations: 🇻🇳
Buon Ma Thuot City Medical Center, Buon Ma Thuot City, Dak Lak, Vietnam

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: S-531011
Drug: pembrolizumab

First Posted Date: 2021-11-01

Last Posted Date: 2024-03-25

Lead Sponsor: Shionogi

Target Recruit Count: 274

Registration Number: NCT05101070

Locations: 🇺🇸
Henry Ford Health Center, Detroit, Michigan, United States
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇺🇸
Angeles Clinic and Research Center, Los Angeles, California, United States

and more 3 locations

Study in Healthy Adults to Quantify Lung Deposition and Distribution of Radio-labelled S-770108 Inhalation Powder Formulation Delivered by a Novel Inhaler Device

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Radio-labelled S-770108
Device: S-770108 Inhaler A1

First Posted Date: 2020-11-17

Last Posted Date: 2020-12-29

Lead Sponsor: Shionogi

Target Recruit Count: 12

Registration Number: NCT04631354

Locations: 🇬🇧
Simbec-Orion, Merthyr Tydfil, United Kingdom

Women's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments

Completed

Conditions: Vulvovaginal Atrophy

First Posted Date: 2020-10-29

Last Posted Date: 2021-06-21

Lead Sponsor: Shionogi

Target Recruit Count: 831

Registration Number: NCT04607707

Locations: 🇪🇸
Clínica Teknon, Barcelona, Spain
🇪🇸
Hospital Universitario de Guadalajara, Guadalajara, Spain
🇪🇸
Instituto Palacios, Madrid, Spain

A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection

Phase 2

Terminated

Conditions: Postoperative Gastrointestinal Dysfunction

Interventions: Drug: Placebo
Drug: Naldemedine

First Posted Date: 2020-04-21

Last Posted Date: 2022-01-18

Lead Sponsor: Shionogi

Target Recruit Count: 2

Registration Number: NCT04355169

Locations: 🇺🇸
Norton Hospital, Louisville, Kentucky, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
CHRISTUS Trinity Clinic Research, Tyler, Texas, United States

and more 5 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy